Therefore, we performed a retrospective study in a patient population with advanced NSCLC to assess the role of genetic variants of genes in JNK and P38α pathways in adverse events in response to platinum-based chemotherapy. This evidence concerns the gene MAPK8 and non-small cell lung carcinoma.